EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

A Marouf iD, N Molinari, D Sibon iD, A S Cottereau, S Kanoun, C Antoine, P E Debureaux, D Cavalieri, L M Fornecker, R O Casasnovas, C Herbaux iD, S Amorim und 6 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18859 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von A Marouf und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France. Hauptthemen laut MEDLINE: Hodgkin Disease, Immunoconjugates, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high‐risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV‐naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV‐exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseImmunoconjugatesHematopoietic Stem Cell TransplantationHumansBrentuximab VedotinRetrospective StudiesStem Cell TransplantationCohort Studies

Stichwörter der Autor:innen

Hodgkin lymphoma relapsebrentuximab vedotin maintenancelong term toxicityprimary refractory diseasetandem stem cell transplantation

Substanzen

Brentuximab VedotinImmunoconjugates

Autor:innen und Institutionen

  • Laboratoire U1163, Institut Imagine, Université Paris Cité, Inserm, Paris, France.
  • Service Hématologie, AP-HP, Hôpital Cochin, Paris, France.
  • Groupe Hospitalier privé Ambroise Paré-Hartmann, Département Recherche Innovation, Neuilly-Sur-Seine, France.
  • IDESP, INSERM, PreMEdical INRIA, Univ Montpellier, CHU Montpellier, Montpellier, France.
  • Paris Est University, Créteil, France.
  • Service Hémopathies Lymphoïdes, AP-HP, Hôpital Henri Mondor, Créteil, France.

ORCID-Profile: A Marouf, D Sibon, C Herbaux, C Rossi, H Ghesquieres, B Deau

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Marouf, A., Molinari, N., Sibon, D., Cottereau, A. S., Kanoun, S., Antoine, C., Debureaux, P. E., Cavalieri, D., Fornecker, L. M., Casasnovas, R. O., Herbaux, C., Amorim, S., Rossi, C., Bouscary, D., Brice, P., Ghesquieres, H., Tamburini, J., & Deau, B. (2023). Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. British Journal of Haematology. https://doi.org/10.1111/bjh.18859

Vancouver

Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, et al. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. British Journal of Haematology. 2023. doi:10.1111/bjh.18859

BibTeX
@article{Marouf2023,
  author = {Marouf, A and Molinari, N and Sibon, D and Cottereau, A S and Kanoun, S and Antoine, C and Debureaux, P E and Cavalieri, D and Fornecker, L M and Casasnovas, R O and Herbaux, C and Amorim, S and Rossi, C and Bouscary, D and Brice, P and Ghesquieres, H and Tamburini, J and Deau, B},
  title = {Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18859}
}
Kostenlos starten →